Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Unknown 2Recruiting 2

Sponsor Class

OTHER_GOV 4OTHER 2INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1

Conditions

Colorectal Neoplasms 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1

Interventions

Cisplatin 49Capecitabine 41apatinib 34Gemcitabine 33Oxaliplatin 32Cyclophosphamide 31Radiotherapy 29Paclitaxel 29Carboplatin 29tislelizumab 27Irinotecan 27Drug Therapy 27Fluorouracil 26Docetaxel 26Bevacizumab 23fludarabine 18Surgical Procedures, Operative 17Nivolumab 17pembrolizumab 16Exercise 16Metformin 15camrelizumab 14S 1 (combination) 14Radiation 13Pemetrexed 13Control Groups 12anlotinib 11Leucovorin 11Vinorelbine 10Standard of Care 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × Etodolac × Clear all
NCT06839144 2025-07-11

OC-POP-PT

Tel-Aviv Sourasky Medical Center

Phase 2 Recruiting
60 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT03838029 2019-11-20

BC-PC

Assaf-Harofeh Medical Center

Phase 2 Unknown
210 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03919461 2019-04-18

COMPIT-2

Assaf-Harofeh Medical Center

Phase 2 Recruiting
200 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT00888797 2011-07-12

β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence

Sheba Medical Center

Phase 3 Unknown
400 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡